Evidence map›Paper›PMID 41843228›Full record

ReviewCurrent obesity reports2026

MASLD In Children - A Distinct Phenotype?

Pervej Alom Barbhuiya, Manash Pratim Pathak

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current obesity reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Pervej Alom BarbhuiyaFaculty of Pharmaceutical Science, Assam down town University, Sankar Madhab Path, Gandhi Nagar, Panikhaiti, Guwahati, 781026, Assam, PIN, India.ORCID http://orcid.org/0000-0001-7483-0857
Manash Pratim PathakFaculty of Pharmaceutical Science, Assam down town University, Sankar Madhab Path, Gandhi Nagar, Panikhaiti, Guwahati, 781026, Assam, PIN, India. manashprpathak@gmail.com.ORCID http://orcid.org/0000-0002-9182-7948

Funding

Indian Council of Medical Research, India 5/4/8-10/Obs/MPP/2022-NCD/II
6 · The paper itself

Abstract

purpose of reviewMetabolic dysfunction-associated steatotic liver disease (MASLD) represents a pattern shift in the classification and understanding of fatty liver disease in adults as well as children, overtaking the previous concept of non-alcoholic fatty liver disease (NAFLD). The adoption of MASLD places a central role of metabolic dysregulation, aligning with the diagnosis and clinical features with underlying cardiometabolic risk factors. Pediatric MASLD requires important focus due to its rising prevalence almost affecting up to 14% of children globally, and over 1/3 of children with obesity because of its distinct pathophysiological, histological, and clinical features compared to adult-onset disease. RECENT

findingsStudies reported that there is a major difference between pediatric and adult MASLD from epidemiology to genetic and metabolic factors to histopathology, and clinical expression. In children, periportal steatosis and fibrosis is prevalent, while in adults the centrilobular pattern is prevalent. Early-life exposures such as maternal obesity, rapid postnatal weight gain, and epigenetic factors amplify pediatric risk and shape the disease phenotype. Socioeconomic status, environmental factors, and sedentary behavior together elevate the pediatric incidence and severity. Due to unique histologic patterns, there are numerous problems associated with diagnosis and treatment. Also, a lack of non-invasive biomarkers and the need for individualized, pediatric-specific treatments that meet both medical and developmental needs should be focused on. Pediatric MASLD comprises a complex clinical and biological phenotype when compared to the adult MASLD in progression and metabolic context. This highlights an urgent need for pediatric-focused research, appropriate diagnostic strategies, and development-specific management protocols. Addressing these gaps is critical to manage the growing burden of MASLD among children worldwide and to improve long-term health outcomes as this population matures into adulthood.

Indexed as

Fatty LiverNon-alcoholic Fatty Liver DiseaseChildHumansPhenotypePrevalenceRisk FactorsFatty liverMASLDNAFLDPediatricPeriportal

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.